<DOC>
	<DOCNO>NCT00003149</DOCNO>
	<brief_summary>RATIONALE : Interleukin-12 may kill tumor cell stop blood flow tumor stimulate person 's blood cell kill multiple myeloma cell . PURPOSE : Randomized phase II trial compare effectiveness interleukin-12 give different time treat patient multiple myeloma .</brief_summary>
	<brief_title>Interleukin-12 Treating Patients With Multiple Myeloma</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate antitumor activity interleukin-12 ( IL-12 ) patient plateau phase multiple myeloma . II . Evaluate toxic effect IL-12 patient . III . Evaluate effectiveness IL-12 augment T helper subset patient . OUTLINE : This randomize study . Patients stratify prior bone marrow transplantation ( yes v ) prior pneumococcal vaccine ( Pnu-Immune-23 ) ( yes vs unknown ) . Patients randomize one two treatment arm : Arm I : Patients receive Haemophilus influenzae b vaccine ( Hib TITER ) Pnu-Immune-23 day 1 week 1 . Patients receive Pnu-Immune-23 within past 3 year receive Hib TITER Pnu-Immune-23 . Patients receive low dose interleukin-12 ( IL-12 ) subcutaneously ( SQ ) twice week week 1 2 . Beginning day 1 week 3 , patient receive high dose IL-12 SQ twice week additional 12 week . Arm II : Patients receive Hib TITER Pnu-Immune-23 arm I . Patients undergo observation week 1-4 , receive low dose IL-12 SQ twice week week 5 6 . Beginning day 1 week 7 , patient receive high dose IL-12 SQ twice week additional 12 week . Both arm : Patients without disease progression may continue receive high dose IL-12 additional 14 week . Patients follow every 3 month first 2 year , every 6 month next 3 year , annually thereafter death . PROJECTED ACCRUAL : A total 40 patient ( 20 per arm ) accrue study .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven plateau phase multiple myeloma original diagnosis : Bone marrow plasmacytosis great 10 % plasma cell , sheet plasma cell , biopsy proven plasmacytoma Must stable plateau phase require objective response , evidence continue improvement criterion , le 20 % variation M protein least 4 week prior study Must least one follow original diagnosis : M protein serum urine Xray evidence osteolytic lesion Measurable evaluable M protein Serum M protein great 1.0 g/dL Urine M protein great 200 mg/24 hour M protein less value consider evaluable ( serum less 1 g/dL urine le 200 mg/24 hour ) Nonsecretory patient ineligible PATIENT CHARACTERISTICS : Age : 18 Performance Status : ECOG 02 Life Expectancy : Not specify Hematopoietic : WBC least 2,500/mm3 Absolute neutrophil count least 1,250/mm3 Platelet count least 100,000/mm3 Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) SGOT le 1.5 time ULN Renal : Creatinine clearance least 50 mL/min Cardiovascular : No New York Heart Association class III IV congestive heart failure Other : Not pregnant nursing Fertile patient must use effective contraception No uncontrolled peptic ulcer disease No inflammatory bowel disease No history significant autoimmune disease ( rheumatoid arthritis systemic lupus erythematosus ) PRIOR CONCURRENT THERAPY : Biologic therapy : At least 60 day since prior biologic response modifier At least 60 day since prior bone marrow transplantation Chemotherapy : At least 60 day since prior chemotherapy Endocrine therapy : No concurrent corticosteroid Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>